The maintenance and repair of bone tissue is primarily attributed to two cell types: osteoblasts which form new bone tissue and osteoclasts which re-absorb bone tissue. Defects in the bone mineralization/bone degradation cycle contribute to a number of bone related diseases such as osteoporosis. Osteoclasts are large, multinucleated cells that play an active role in bone resorption. The Poietics Osteoclast Precursor Cell system has been designed for use in high-throughput applications to conduct research on osteoporosis, bone resorption, and other bone-related diseases. Monocytes from the marrow or the blood serve as precursors of osteoclasts. Traditionally, researchers drive populations of purified monocytes to become osteoclasts, however, in some cases, this can result in a differentiation efficiency of as low as 10%. In contrast, Lonza's Osteoclast Precursor Cell System yields up to 50% conversion of precursors to osteoclasts when differentiated. Cryopreserved Poietics Human Osteoclast Precursor Cells (OCPs) are guaranteed to contain ≥1 million viable cells per ampoule and test positive for osteoclast activity and stain for TRAP following differentiation. HIV-1, hepatitis B and hepatitis C are not detected for all donors and/or cell lots.
English
Deutsch
